Date: 2014-05-30
Type of information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: GSK (UK)
Product: subcutaneous ofatumumab
Action mechanism:
Disease: relapsing-remitting multiple sclerosis
Therapeutic area: Neurodegenerative diseases
Country:
Trial details:
Latest
news: * On May 30, 2014, Genmab announced its collaboration partner GSK has taken the decision to start additional pivotal studies with the subcutaneous formulation of ofatumumab. Phase III studies of subcutaneous ofatumumab in RRMS are expected to begin in 2015, following encouraging data from a Phase II study reported in October 2013. Further details about the RRMS program will be available in due course.
